NFNathan R. Foster

Nathan R. Foster

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nathan R. Foster has a total of 109 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer

    by Ashwin Ganti, Patrick W. McGarrah, Harry Fuentes Bayne, Casey Fazer-Posorske, Binav Baral, Daniel J. Ma, Scott C. Lester, David M. Routman, Michelle A. Neben-Wittich, Jessica M. Wilson, et al.

    Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.

  • 470 - Randomized Placebo-Controlled Trial of Difluoromethylornithine (DFMO) Plus Aspirin for the Prevention of Colorectal Adenoma Recurrence and Reduction in Aberrant Crypt Foci (ACF) in Patients with Prior Advanced Adenomas or Cancer

    by Frank A. Sinicrope, Pruthvi R. Velamala, Louis M. Wong Kee Song, Thomas R. Viggiano, David H. Bruining, Elizabeth Rajan, Christopher Gostout, Robert E. Kraichely, Navtej S. Buttar, Kenneth W. Schroeder, et al.

  • Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.

    by Frank A. Sinicrope, Thomas C. Smyrk, Nathan R. Foster, Jeffrey P. Meyers, Stephen N. Thibodeau, Richard M. Goldberg, Qian Shi, Daniel J. Sargent, Steven R. Alberts

    3518 Background: High levels of TILs are associated with favorable prognosis in some solid tumors. We examined TIL levels in CC subtyped using mutations in KRAS or BRAF oncogenes as well as DNA mismatch repair (MMR) status, and examined association with patient (pt) prognosis. Methods: Stage III CC (N=2293) from a randomized trial of adjuvant FOLFOX + cetuximab (NCCTG N0147) were analyzed for TILs; dichotomized as high (> 4 TILs per HPF) vs low at light microscopy. We determined the association of TILs with clinicopathological features, mutations in KRAS exon 2 or BRAF(V600E), MMR status, and DFS by multivariate Cox regression analyses. Results: Higher TIL densities were found in tumors with wild-type (wt) vs mutated (mut) KRAS (p=.038) or BRAF (p<.0001). Among tumors with mut BRAFV600E or mut KRAS, high vs low TILs were found in 19.2% and 9.5%, respectively. In tumors with mut BRAF, high TILs were detected in 31.2% of dMMR vs 9.5% of pMMR cancers (p<.0001). TILs were increased 3.6-fold in dMMR vs proficient (p) MMR tumors (p<.0001). Also associated with high vs low TILs were female vs male (p=.011), white vs non-white (p=.008), proximal vs distal (p<.0001), lower T stage (p=.004), fewer positive/examined nodes (p=.015), and high vs low grade (p=.0001). High vs low TILs were associated with better DFS overall [HR=0.76 (0.57-1.01), p=0.047], and among tumors with wt KRAS [HR= 0.61 (0.41-.89), p=.006] or wt KRAS and BRAF [HR= 0.56 (0.34-.92), p=.013]. TILs were not prognostic in tumors with mut KRAS (p=.71; TIL*KRAS interaction p= 0.097) or mut BRAF (p=.18). High vs low TILs were associated with favorable DFS in pt tumors with dMMR [HR= 0.55 (.30-1.01), p=.045], but not pMMR (p=.301; interaction p=0.17]. No significant differences were found by treatment arm. Conclusions: Significantly lower TILs are found in tumors with mut vs wt KRAS or BRAF suggesting reduced immunogenicity. Among tumors with wt, but not mut, KRAS and BRAF, high vs low TILs were associated with better survival. TILs were increased 3.6-fold in dMMR vs pMMR, and favorably prognostic within dMMR pts. These results for wt tumors and those with dMMR suggest that immune activation improves survival outcomes.


  • Mutation analysis in metastatic colorectal cancers (mCRC) subjected to gene panel testing for BRAF and KRAS genes in clinical practice.

    by Jeremy Clifton Jones, Frank A. Sinicrope, Nathan R. Foster, Benjamin Kipp, Jesse S Voss

    E15049 Background: While RAS and BRAF mutations predict resistance to anti-EGFR therapy, the mechanisms of secondary or acquired resistance to these drugs in patients (pts) with wild-type (wt) RAS/RAF tumors are poorly understood, as are molecular alterations that confer resistance to BRAF inhibitors in BRAFMut CRCs. We compared non-RAS/RAF mutational frequencies among pts with RASmut, BRAFMut and wt RAS/BRAFtumors in an effort to identify potential drivers of resistance to targeted therapies. Methods: We identified 270 pts from a database which included all pts with mCRC who had targeted next-generation sequencing of clinical tumor specimens between 2013-2015 at Mayo Clinic. The 3 groups (RASmut, BRAFMut and wt RAS/BRAF) were compared for mutation frequencies in 46 additional cancer-related genes. Results: Among all pts with mCRC, mutations were most common in the APC, KRAS and TP53 genes which accounted for 18.8%, 20.3% and 28.0% of all mutations, respectively. There were significant differences in the frequencies of commonly mutated genes of known function within the 3 groups. Compared to wt RAS/BRAF, BRAFMut tumors had significantly fewer APC (p = 0.0194) and TP53 (p = 0.0061) mutations, yet significantly more AKT (p = 0.0048) and MET (p = 0.0235) mutations. RASmuttumors had significantly more APC (p = 0.0008) and PIK3CA (p = 0.0064) mutations and fewer TP53mutations (p = 0.0004) compared with wt RAS/BRAF. Conclusions: We found significant heterogeneity in the mutational spectrum within mCRC according to whether they harbor RAS or BRAFV600E mutations. Tumors with BRAFV600E were enriched in AKT and MET mutations that have been implicated in resistance to BRAF-inhibition in mCRC. RASmuttumors had highest rates of APC mutations indicating dependence the Wnt signaling pathway in these tumors. These data identify important pathogenic mutations that likely play a role in pathogenesis and are potentially actionable in patients with mCRCs.

  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer

    by Nathan R. Foster, Lindsay A. Renfro, Steven E. Schild, Mary W. Redman, Xiaofei F. Wang, Suzanne E. Dahlberg, Keyue Ding, Penelope A. Bradbury, Suresh S. Ramalingam, David R. Gandara, et al.


  • Open Access

    Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy

    by Jae Myung Park, Shengbing Huang, Tsung-Teh Wu, Nathan R. Foster, Frank A. Sinicrope

    Autophagy is a cellular degradation process that can be activated in tumor cells to confer stress tolerance. During autophagy initiation and autophagosome formation, Beclin 1 binds microtubule-associated protein-1 light chain 3 (LC3I) that is converted to its membrane-bound form (LC3II) and interacts with the ubiquitin-binding protein p62/sequestosome 1 (SQSTM1). We determined the association of Beclin 1, LC3 and p62 protein expression with clinical outcome in resected stage II and III colon carcinomas (n = 178) from participants in 5-fluororuacil (5-FU)-based adjuvant therapy trials. The immunopercentage for each marker was determined and dichotomized for analysis with overall survival (OS) using Cox models. We found that autophagy markers localized to the tumor cell cytoplasm and showed increased expression relative to normal epithelial cells. Overexpression of Beclin 1, LC3 and p62 proteins were detected in 69%, 79% and 85% of tumors, respectively. Expression levels were not significantly associated with clinicopathological variables. In a multivariable analysis adjusting for tumor grade, stage and patient age, Beclin 1 overexpression was independently associated with worse OS [hazard ratio (HR), 1.82; 95% confidence interval (CI), 1.0–3.3; p = 0.042] in patients who received 5-FU-based adjuvant therapy. Neither LC3 nor p62 overexpression was prognostic. In conclusion, Beclin 1 overexpression was associated with reduced survival in colon cancer patients treated with adjuvant 5-FU. These data are consistent with preclinical evidence indicating that autophagy can protect colon cancer cells from 5-FU and support the targeting of autophagy for therapeutic advantage in this malignancy.


  • Abstract PR-03: Aspirin mediated downregulation of Warburg kinase AKT1 in patients with Barrett's esophagus: Implications in neoplastic transformation

    by Navtej S. Buttar, Gary W. Falk, Cathrine J. DeMars, Sonia Chowdhury, Ahmed Elebiary, Anamay Sharma, Sidhartha Chaudhry, Nathan R. Foster, Katie L. Allen Ziegler, Yvonne Romero, et al.

    Background: In patients with Barrett's esophagus, chronic reflux injury and inflammation are associated with esophageal adenocarcinoma, one of the most rapidly increasing lethal cancers. Epidemiological and preclinical studies support decreased risk of esophageal adenocarcinoma with NSAID use. Gastroesophageal refluxate contents can promote carcinogenesis in Barrett's metaplasia by activating AKT, which up regulates COX-2 expression and prostaglandin biosynthesis. We recently noted that neoplastic transformation in Barrett's esophagus is associated with increased AKT expression, particularly isoform AKT1. The AIM of this study is to investigate the effect of NSAID (Aspirin) use in patients with Barrett's esophagus on AKT1 expression using frozen tissue from the randomized, phase II trial of aspirin and esomeprazole for esophageal cancer chemoprevention in Barrett's esophagus patients and to assess the functional consequences of AKT1 expression in-vitro. Methods and Results: In a subset of patients (12 of 120 patients) with Barrett's esophagus who were randomized to placebo, lower dose (81 mg) or higher dose (325 mg) Aspirin for 4 weeks, both PCR and Western blot revealed marked reduction in AKT1 expression in patients who received 325 mg of Aspirin daily compared to patients who received placebo. Our in-vitro experiments support that AKT1 expression is functionally relevant to the process of carcinogenesis in Barrett's epithelial cells. Using adenovirus to induce AKT1 expression, we show that increased AKT1 expression increases Barrett's epithelial cell growth, facilitates RAS-mediated transformation of pre-neoplastic epithelial cells and promotes colony formation. Since AKT1 is known as Warburg kinase and regulates cellular glucose uptake to support aerobic glycolysis during growth de-regulation and neoplasia, we examined the uptake of fluorescent deoxyglucose analog (2-NBDG) in Barrett's epithelial cells transduced with AKT1 adenovirus. At 48 hrs, compared to control, AKT1 overexpression resulted in increased glucose uptake both by metaplastic and neoplastic Barrett's epithelial cells. Transcriptional repression of AKT1 abrogated the 2-NBDG uptake by these cells. Finally, we did pathway specific qPCRs and noted that use of Aspirin is associated with altered expression of chromatin remodelers that could down-regulate AKT1 expression. Conclusion: Collectively, our results demonstrate that Aspirin mediated down-regulation of Warburg kinase AKT1 in patients with Barrett?s esophagus is a novel mechanism for the regulation of Barrett?s epithelial cell growth. The in-depth characterization of molecular mechanisms is currently underway. This abstract is also presented as Poster A82. Citation Format: Navtej S. Buttar, Gary W. Falk, Cathrine J. DeMars, Sonia Chowdhury, Ahmed Elebiary, Anamay Sharma, Sidhartha Chaudhry, Nathan R. Foster, Katie L. Allen Ziegler, Yvonne Romero, Norman E. Marcon, Thomas Schnell, Douglas A. Corley, Prateek Sharma, Marcia R. Cruz-Correa, Chin Hur, David E. Fleischer, Amitabh Chak, Kenneth R. DeVault, David S. Weinberg, Gary Della’Zanna, Ellen Richmond, Thomas C. Smyrk, Sumithra Mandrekar, Paul J. Limburg. Aspirin mediated downregulation of Warburg kinase AKT1 in patients with Barrett's esophagus: Implications in neoplastic transformation. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr PR-03.


  • Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair.

    by Harry H. Yoon, Jared M Orrock, Nathan R. Foster, Daniel J. Sargent, Thomas C. Smyrk, Frank Sinicrope

    460 Background: The immune response has emerged as a strong prognostic factor in colon cancer. Whereas CD8+ T cells mediate antitumor response, regulatory T cells expressing FoxP3+ can antagonize this effect, though prognostic data conflict. These markers have yet to be analyzed with MMR status, which is important since dMMR tumors show enhanced immune response. Methods: CD8+ and FoxP3+ density were analyzed by immunohistochemistry (IHC) in resected stage II and III colon carcinomas (N = 216) from participants in phase III adjuvant 5-fluorouracil-based trials. High vs low immune density was dichotomized at the median. MMR status, determined by IHC or analysis of microsatellite instability, was categorized as dMMR (12%) or proficient MMR (pMMR). Cox models, stratified by study, were adjusted for age, stage, grade and, where noted, MMR. Results: The association of FoxP3+ density with overall survival (OS) differed by CD8+ density (P for interaction = .040). By multivariable analysis, FoxP3+high was significantly associated with improved OS in CD8+low tumors (hazard ratio 0.43 [95% confidence interval 0.19 – 0.95]; P = .030], but not in CD8+high tumors (P = .91). Results were consistent after MMR adjustment. We then determined their prognostic impact in the larger pMMR subset (N = 119). Tumors with high FoxP3+ were associated with improved OS in cases with low, but not high, CD8+ density ( Table ). These patients (FoxP3+high, CD8+low) had similar 5-year OS rates as 107 dMMR cases from parent studies (89% vs 80%; P = .74), despite having distinct clinicopathologic features. Conclusions: The prognostic impact of FoxP3+ T cells depends on CD8+, indicating the importance of analyzing both in combination. High FoxP3+ exerts a paradoxically favorable survival impact, but only when CD8+ is low. Survival in pMMR tumors with high FoxP3+ and low CD8+ was similar to that of dMMR tumors, indicating that a favorable pMMR subset can be identified. [Table: see text]

  • Open Access

    Tumor response and progression‐free survival as potential surrogate endpoints for overall survival in extensive stage small‐cell lung cancer

    by Nathan R. Foster, Yingwei Qi, Qian Shi, James E. Krook, John W. Kugler, James R. Jett, Julian R. Molina, Steven E. Schild, Alex A. Adjei, Sumithra J. Mandrekar

    BACKGROUND: The authors investigated the putative surrogate endpoints of best response, complete response (CR), confirmed response, and progression‐free survival (PFS) for associations with overall survival (OS), and as possible surrogate endpoints for OS.METHODS: Individual patient data from 870 untreated extensive stage small‐cell lung cancer patients participating in 6 single‐arm (274 patients) and 3 randomized trials (596 patients) were pooled. Patient‐level associations between putative surrogate endpoints and OS were assessed by Cox models using landmark analyses. Trial‐level surrogacy of putative surrogate endpoints were assessed by the association of treatment effects on OS and individual putative surrogate endpoints. Trial‐level surrogacy measures included:R2from weighted least squares regression model, Spearman correlation coefficient, andR2from bivariate survival model (CopulaR2).RESULTS: Median OS and PFS were 9.6 (95% confidence interval [CI], 9.1‐10.0) and 5.5 (95% CI, 5.2‐5.9) months, respectively; best response, CR, and confirmed response rates were 44%, 22%, and 34%, respectively. Patient‐level associations showed that PFS status at 4 months was a strong predictor of subsequent survival (hazard ratio [HR], 0.42; 95% CI, 0.35‐0.51; concordance index 0.63;P< .01), with 6‐month PFS being the strongest (HR, 0.41; 95% CI, 0.35‐0.49; concordance index, 0.66,P< .01). At the trial level, PFS showed the highest level of surrogacy for OS (weighted least squaresR2= 0.79; CopulaR2= 0.80), explaining 79% of the variance in OS. Tumor response endpoints showed lower surrogacy levels (weighted least squaresR2≤0.48).CONCLUSIONS: PFS was strongly associated with OS at both the patient and trial levels. PFS also shows promise as a potential surrogate for OS, but further validation is needed using data from a larger number of randomized phase 3 trials. Cancer 2011. © 2010 American Cancer Society.